Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1979 2
1980 4
1981 4
1982 13
1983 4
1984 5
1985 26
1986 21
1987 32
1988 22
1989 18
1990 21
1991 21
1992 36
1993 46
1994 76
1995 63
1996 71
1997 69
1998 71
1999 93
2000 98
2001 93
2002 153
2003 200
2004 239
2005 324
2006 431
2007 430
2008 511
2009 633
2010 760
2011 940
2012 1092
2013 1272
2014 1423
2015 1687
2016 1796
2017 2001
2018 2213
2019 2679
2020 3117
2021 3490
2022 4193
2023 4062
2024 4387
2025 87

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

34,905 results

Results by year

Filters applied: . Clear all
Page 1
Repotrectinib in ROS1 Fusion-Positive Non-Small-Cell Lung Cancer.
Drilon A, Camidge DR, Lin JJ, Kim SW, Solomon BJ, Dziadziuszko R, Besse B, Goto K, de Langen AJ, Wolf J, Lee KH, Popat S, Springfeld C, Nagasaka M, Felip E, Yang N, Velcheti V, Lu S, Kao S, Dooms C, Krebs MG, Yao W, Beg MS, Hu X, Moro-Sibilot D, Cheema P, Stopatschinskaja S, Mehta M, Trone D, Graber A, Sims G, Yuan Y, Cho BC; TRIDENT-1 Investigators. Drilon A, et al. Among authors: hu x. N Engl J Med. 2024 Jan 11;390(2):118-131. doi: 10.1056/NEJMoa2302299. N Engl J Med. 2024. PMID: 38197815 Clinical Trial.
Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study.
Qin S, Chan SL, Gu S, Bai Y, Ren Z, Lin X, Chen Z, Jia W, Jin Y, Guo Y, Hu X, Meng Z, Liang J, Cheng Y, Xiong J, Ren H, Yang F, Li W, Chen Y, Zeng Y, Sultanbaev A, Pazgan-Simon M, Pisetska M, Melisi D, Ponomarenko D, Osypchuk Y, Sinielnikov I, Yang TS, Liang X, Chen C, Wang L, Cheng AL, Kaseb A, Vogel A; CARES-310 Study Group. Qin S, et al. Among authors: hu x. Lancet. 2023 Sep 30;402(10408):1133-1146. doi: 10.1016/S0140-6736(23)00961-3. Epub 2023 Jul 24. Lancet. 2023. PMID: 37499670 Clinical Trial.
The third Intensive Care Bundle with Blood Pressure Reduction in Acute Cerebral Haemorrhage Trial (INTERACT3): an international, stepped wedge cluster randomised controlled trial.
Ma L, Hu X, Song L, Chen X, Ouyang M, Billot L, Li Q, Malavera A, Li X, Muñoz-Venturelli P, de Silva A, Thang NH, Wahab KW, Pandian JD, Wasay M, Pontes-Neto OM, Abanto C, Arauz A, Shi H, Tang G, Zhu S, She X, Liu L, Sakamoto Y, You S, Han Q, Crutzen B, Cheung E, Li Y, Wang X, Chen C, Liu F, Zhao Y, Li H, Liu Y, Jiang Y, Chen L, Wu B, Liu M, Xu J, You C, Anderson CS; INTERACT3 Investigators. Ma L, et al. Among authors: hu x. Lancet. 2023 Jul 1;402(10395):27-40. doi: 10.1016/S0140-6736(23)00806-1. Epub 2023 May 25. Lancet. 2023. PMID: 37245517 Free PMC article. Clinical Trial.
Fractional Flow Reserve or Intravascular Ultrasonography to Guide PCI.
Koo BK, Hu X, Kang J, Zhang J, Jiang J, Hahn JY, Nam CW, Doh JH, Lee BK, Kim W, Huang J, Jiang F, Zhou H, Chen P, Tang L, Jiang W, Chen X, He W, Ahn SG, Yoon MH, Kim U, Lee JM, Hwang D, Ki YJ, Shin ES, Kim HS, Tahk SJ, Wang J; FLAVOUR Investigators. Koo BK, et al. Among authors: hu x. N Engl J Med. 2022 Sep 1;387(9):779-789. doi: 10.1056/NEJMoa2201546. N Engl J Med. 2022. PMID: 36053504 Clinical Trial.
The Culprit Behind HBV-Infected Hepatocytes: NTCP.
Li S, Hao L, Deng J, Zhang J, Yu F, Ye F, Li N, Hu X. Li S, et al. Among authors: hu x. Drug Des Devel Ther. 2024 Oct 28;18:4839-4858. doi: 10.2147/DDDT.S480151. eCollection 2024. Drug Des Devel Ther. 2024. PMID: 39494152 Free PMC article. Review.
A metabolome-derived score predicts metabolic dysfunction-associated steatohepatitis and mortality from liver disease.
Huang Q, Qadri SF, Bian H, Yi X, Lin C, Yang X, Zhu X, Lin H, Yan H, Chang X, Sun X, Ma S, Wu Q, Zeng H, Hu X, Zheng Y, Yki-Järvinen H, Gao X, Tang H, Xia M. Huang Q, et al. Among authors: hu x. J Hepatol. 2024 Oct 16:S0168-8278(24)02636-9. doi: 10.1016/j.jhep.2024.10.015. Online ahead of print. J Hepatol. 2024. PMID: 39423864 Free article.
ITGA5+ synovial fibroblasts orchestrate proinflammatory niche formation by remodelling the local immune microenvironment in rheumatoid arthritis.
Zheng L, Gu M, Li X, Hu X, Chen C, Kang Y, Pan B, Chen W, Xian G, Wu X, Li C, Wang C, Li Z, Guan M, Zhou G, Mobasheri A, Song W, Peng S, Sheng P, Zhang Z. Zheng L, et al. Among authors: hu x. Ann Rheum Dis. 2024 Nov 1:ard-2024-225778. doi: 10.1136/ard-2024-225778. Online ahead of print. Ann Rheum Dis. 2024. PMID: 39486872
34,905 results
You have reached the last available page of results. Please see the User Guide for more information.